China SXT Pharmaceuticals secures $100,000 in share sale

Published 13/05/2025, 16:46
China SXT Pharmaceuticals secures $100,000 in share sale

China SXT Pharmaceuticals, Inc., a pharmaceutical company specializing in the research, development, manufacturing, and sales of Traditional Chinese Medicine Pieces (TCMPs), has entered into a securities purchase agreement with an investor for the sale of 200,000 ordinary shares, raising gross proceeds of approximately $100,000. This transaction was finalized on Monday, with the company disclosing the details in a report filed with the U.S. Securities and Exchange Commission today.

The offering, which closed on May 12, 2025, was conducted under a prospectus supplement filed with the SEC as part of a shelf registration statement on Form F-3, which became effective on November 4, 2024. The base prospectus for this offering was dated October 22, 2024. As a result of this offering, the total number of issued and outstanding ordinary shares of the company is now 16,027,758.

The company has stated that the proceeds from the offering are expected to be $100,000 before the deduction of offering expenses. However, the specific use of these funds has not been disclosed. The securities were issued pursuant to the registration statement previously filed and declared effective, with the sale conducted in compliance with the applicable securities laws.

China SXT Pharmaceuticals has made it clear that the report on Form 6-K shall not be considered as an offer to sell or a solicitation of an offer to buy any securities.

The details provided in the SEC filing are strictly factual and are based on the company’s official statement. The information presented is intended for investors and the broader market to understand the recent financial activities of China SXT Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.